<?xml version="1.0" encoding="UTF-8"?>
<ref id="B32-cancers-12-00713">
 <label>32.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Rassidakis</surname>
    <given-names>G.Z.</given-names>
   </name>
   <name>
    <surname>Herold</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Myrberg</surname>
    <given-names>I.H.</given-names>
   </name>
   <name>
    <surname>Tsesmetzis</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Rudd</surname>
    <given-names>S.G.</given-names>
   </name>
   <name>
    <surname>Henter</surname>
    <given-names>J.-I.</given-names>
   </name>
   <name>
    <surname>Schaller</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Ng</surname>
    <given-names>S.-B.</given-names>
   </name>
   <name>
    <surname>Chng</surname>
    <given-names>W.J.</given-names>
   </name>
   <name>
    <surname>Yan</surname>
    <given-names>B.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens</article-title>
  <source>Blood Cancer J.</source>
  <year>2018</year>
  <volume>8</volume>
  <fpage>98</fpage>
  <pub-id pub-id-type="doi">10.1038/s41408-018-0134-z</pub-id>
  <?supplied-pmid 30341277?>
  <pub-id pub-id-type="pmid">30341277</pub-id>
 </element-citation>
</ref>
